Cardinal Health sees 15% revenue growth in Pharma segment, driven by precision medicine and gene therapy.

Cardinal Health's Pharmaceutical and Specialty Solutions segment reported $234.8 billion in revenues for FY2026, up 15% year-over-year and representing 92% of total company revenues. The company is positioned for further growth through its exposure to precision medicine, which is expected to grow at a 17% CAGR, and advancements in gene therapy and Solaris Health. Despite trading at a fair price-to-sales ratio and forecasting 8.18% forward revenue growth, Cardinal Health faces risks from tariff volatility and supply chain pressures. This growth trajectory highlights the company's potential to capture a significant share of an underserved market and support long-term revenue expansion.